AIM To assess the diagnostic value of FIB-4, aspartate aminotransferase-to-platelet ratio index(APRI), and liver stiffness measurement(LSM) in patients with hepatitis B virus infection who have persistently normal ala...AIM To assess the diagnostic value of FIB-4, aspartate aminotransferase-to-platelet ratio index(APRI), and liver stiffness measurement(LSM) in patients with hepatitis B virus infection who have persistently normal alanine transaminase(PNALT).METHODS We enrolled 245 patients with chronic hepatitis B: 95 in PNALT group, 86 in intermittently elevated alanine transaminase(PIALT1) group [alanine transaminase(ALT) within 1-2 × upper limit of normal value(ULN)], and 64 in PIALT2 group(ALT > 2 × ULN). All the patients received a percutaneous liver biopsy guided by ultrasonography. LSM, biochemical tests, and complete blood cell counts were performed.RESULTS The pathological examination revealed moderate inflammatory necrosis ratios of 16.81%(16/95), 32.56%(28/86), and 45.31%(28/64), and moderate liverfibrosis of 24.2%(23/95), 33.72%(29/86), and 43.75%(28/64) in the PNALT, PIALT1, and PIALT2 groups, respectively. The degrees of inflammation and liver fibrosis were significantly higher in the PIALT groups than in the PNALT group(P < 0.05). No significant difference was found in the areas under the curve(AUCs) between APRI and FIB-4 in the PNALT group; however, significant differences were found between APRI and LSM, and between FIB-4 and LSM in the PNALT group(P < 0.05 for both). In the PIALT1 and PIALT2 groups, no significant difference(P > 0.05) was found in AUCs for all comparisons(P > 0.05 for all). In the overall patients, a significant difference in the AUCs was found only between LSM and APRI(P < 0.05).CONCLUSION APRI and FIB-4 are not the ideal noninvasive hepatic fibrosis markers for PNALT patients. LSM is superior to APRI and FIB-4 in PNALT patients because of the influence of liver inflammation and necrosis.展开更多
AIM: To investigate the combined diagnostic accuracy of acoustic radiation force impulse(ARFI), aspartate aminotransferase to platelet ratio index(APRI) and Forns index for a non-invasive assessment of liver fibrosis ...AIM: To investigate the combined diagnostic accuracy of acoustic radiation force impulse(ARFI), aspartate aminotransferase to platelet ratio index(APRI) and Forns index for a non-invasive assessment of liver fibrosis in patients with chronic hepatitis B(CHB). METHODS: In this prospective study, 206 patients had CHB with liver fibrosis stages F0-F4 classified by METAVIR and 40 were healthy volunteers were measured by ARFI, APRI and Forns index separately or combined as indicated. RESULTS: ARFI, APRI or Forns index demonstrated a significant correlation with the histological stage(all P < 0.001). According to the AUROC of ARFI and APRI for evaluating fibrotic stages more than F2, ARFI showed an enhanced diagnostic accuracy than APRI(P < 0.05). The combined measurement of ARFI and APRI exhibited better accuracy than ARFI alone when evaluating ≥ F2 fibrotic stage(Z = 2.77, P = 0.006). Combination of ARFI, APRI and Forns index did not obviously improve the diagnostic accuracy compared to the combination of ARFI and APRI(Z = 0.958, P = 0.338). CONCLUSION: ARFI + APRI showed enhanced diagnostic accuracy than ARFI or APRI alone for significant liver fibrosis and ARFI + APRI + Forns index shows the same effect with ARFI + APRI.展开更多
AIM To investigate the usefulness of aspartate aminotransferase to platelet ratio index(APRI) in predicting hepatocellular carcinoma(HCC) risk in primary biliary cholangitis(PBC).METHODS We identified PBC patients bet...AIM To investigate the usefulness of aspartate aminotransferase to platelet ratio index(APRI) in predicting hepatocellular carcinoma(HCC) risk in primary biliary cholangitis(PBC).METHODS We identified PBC patients between 2000 and 2015 by searching the electronic medical database of a tertiary center. The hazard ratio(HR) of HCC with different risk factors was determined by Cox proportional hazards model. RESULTS One hundred and forty-four PBC patients were recru-ited. Patients were diagnosed at a median age of 57.8 years [interquartile range(IQR): 48.7-71.5 years), and 41(28.5%) patients had cirrhosis at baseline. The median follow-up duration was 6.9 years(range: 1.0-26.3 years). Twelve patients developed HCC, with an incidence rate of 10.6 cases per 1000 patient-years. The overall 5-, 10-and 15-year cumulative incidences of HCC were 2.3% 95%CI: 0%-4.8%), 8.4%(95%CI: 1.8%-14.5%) and 21.6%(6.8%-34.1%), respectively. Older age(HR = 1.07), cirrhosis(HR = 4.38) and APRI at 1 year after treatment(APRI-r1) > 0.54(HR = 3.94) were independent factors for HCC development. APRI-r1, when combined with treatment response, further stratified HCC risk(log rank P < 0.05). The area under receiver operating curve of APRI-r1 in predicting HCC was 0.77(95%CI: 0.64-0.88).CONCLUSION APRI-r1 can be used to predict the development of HCC in PBC patients. Combination of APRI-r1 with treatment response can further stratify the HCC risk.展开更多
目的探究天冬氨酸转氨酶和血小板比率指数(aspartate aminotransferase-to-platelet ratio index,APRI)与妊娠期肝内胆汁淤积症(intrahepatic cholestasis of pregnancy,ICP)的相关性。方法选取安徽医科大学附属巢湖医院产科于2021年9月...目的探究天冬氨酸转氨酶和血小板比率指数(aspartate aminotransferase-to-platelet ratio index,APRI)与妊娠期肝内胆汁淤积症(intrahepatic cholestasis of pregnancy,ICP)的相关性。方法选取安徽医科大学附属巢湖医院产科于2021年9月至2023年3月收治的70例ICP孕妇作为病例组,选择同期70名健康孕妇作为对照组。采用回顾性研究方法,收集并分析两组孕妇分娩前1周的一般资料及实验室资料,并用t检验进行两组间的比较。运用Pearson相关系数法分析APRI与总胆汁酸(total bile acid,TBA)相关性;Logistic回归分析APRI与ICP的关系,采用受试者操作特征(receiver operating characteristic,ROC)曲线评估APRI在ICP中的应用价值。结果ICP组的APRI(1.1±1.2)高于对照组(0.2±0.1),差异有统计学意义(P<0.05)。重度ICP组的APRI(1.9±2.2)与轻度ICP组(0.9±0.7)比较,差异无统计学意义(P>0.05)。在ICP组中,APRI与TBA呈正相关(r=0.657,P<0.05)。Logistic回归分析结果表明,APRI不是ICP发生的独立影响因素(P>0.05)。APRI的曲线下面积(area under the curve,AUC)为0.870(P<0.05)。结论APRI与ICP的发生及其发展有一定的相关性,而对ICP的病情评估未显示出确定价值。展开更多
BACKGROUND Both tenofovir alafenamide(TAF)and tenofovir disoproxil fumarate(TDF)are the first-line treatments for chronic hepatitis B(CHB).We have showed switching from TDF to TAF for 96 weeks resulted in further alan...BACKGROUND Both tenofovir alafenamide(TAF)and tenofovir disoproxil fumarate(TDF)are the first-line treatments for chronic hepatitis B(CHB).We have showed switching from TDF to TAF for 96 weeks resulted in further alanine aminotransferase(ALT)improvement,but data remain lacking on the long-term benefits of TDF switching to TAF on hepatic fibrosis.AIM To assess the benefits of TDF switching to TAF for 3 years on ALT,aspartate aminotransferase(AST),and hepatic fibrosis improvement in patients with CHB.METHODS A single center retrospective study on 53 patients with CHB who were initially treated with TDF,then switched to TAF to determine dynamic patterns of ALT,AST,AST to platelet ratio index(APRI),fibrosis-4(FIB-4)scores,and shear wave elastography(SWE)reading improvement at switching week 144,and the associated factors.RESULTS The mean age was 55(28-80);45.3%,males;15.1%,clinical cirrhosis;mean baseline ALT,24.8;AST,25.7 U/L;APRI,0.37;and FIB-4,1.66.After 144 weeks TDF switching to TAF,mean ALT and AST were reduced to 19.7 and 21,respectively.From baseline to switching week 144,the rates of ALT and AST<35(male)/25(female)and<30(male)/19(female)were persistently increased;hepatic fibrosis was also improved by APRI<0.5,from 79.2%to 96.2%;FIB-4<1.45,from 52.8%to 58.5%,respectively;mean APRI was reduced to 0.27;FIB-4,to 1.38;and mean SWE reading,from 7.05 to 6.30 kPa after a mean of 109 weeks switching.The renal function was stable and the frequency of patients with glomerular filtration rate>60 mL/min was increased from 86.5%at baseline to 88.2%at switching week 144.CONCLUSION Our data confirmed that switching from TDF to TAF for 3 years results in not only persistent ALT/AST improvement,but also hepatic fibrosis improvement by APRI,FIB-4 scores,as well as SWE reading,the important clinical benefits of long-term hepatitis B virus antiviral treatment with TAF.展开更多
目的:探讨aMAP(age-male-ALBI-platelet,aMAP)、天门冬氨酸氨基转移酶/血小板比率指数(aspartate aminotransferase-to-platelet ratio index,APRI)、基于4因子的肝纤维化指数(fibrosis index based on the 4 factors,FIB-4)及肝硬度值(...目的:探讨aMAP(age-male-ALBI-platelet,aMAP)、天门冬氨酸氨基转移酶/血小板比率指数(aspartate aminotransferase-to-platelet ratio index,APRI)、基于4因子的肝纤维化指数(fibrosis index based on the 4 factors,FIB-4)及肝硬度值(liver stiffness measurement,LSM)评估乙型肝炎(乙肝)肝硬化患者食管胃静脉曲张(esophageal gastric varices,EGV)程度的价值。方法:选取2018年4月到2022年5月期间在上海交通大学医学院附属瑞金医院确诊并接受治疗的乙肝肝硬化患者114例,对其进行肝功能、血常规、LSM、胃镜等检查,根据计算公式计算aMAP、APRI、FIB-4。根据胃镜结果将患者分为无EGV组(39例)、轻度EGV组(30例)、中度EGV组(23例)及重度EGV组(22例),比较4组间的aMAP、APRI、FIB-4。采用受试者操作特征曲线(receiver operator characteristic curve,ROC曲线)分析aMAP、APRI、FIB-4及LSM评估乙肝肝硬化患者EGV程度的价值。结果:EGV患者(包括轻度、中度及重度EGV组)的aMAP、APRI、FIB-4、LSM均显著高于无EGV的患者,差异有统计学意义(P<0.05)。轻度、中度及重度EGV组间的aMAP、APRI、FIB-4差异均有统计学意义(P<0.05);轻度EGV组与中度、重度EGV组间LSM差异有统计学意义(P<0.05)。aMAP评估EGV程度的ROC曲线下面积(the area under ROC curve,AUROC)为0.76,灵敏度为85.9%,特异度为65.7%;APRI、FIB-4和LSM评估EGV程度的AUROC分别为0.86、0.85、0.79,灵敏度分别为81.30%、82.80%、88.40%,特异度分别为82.90%、77.10%、66.80%。aMAP、APRI、FIB-4和LSM对肝硬化患者是否合并EGV有较好诊断价值(P<0.05)。aMAP、APRI、FIB-4对乙肝肝硬化患者的EGV程度有一定诊断价值(P<0.05),但特异度较低。结论:aMAP、APRI、FIB-4及LSM诊断乙肝肝硬化患者伴EGV的价值较高,而aMAP、APRI及FIB-4对其EGV程度有一定评估价值,可作为不适合做胃镜患者评估EGV的补充参考,为EGV的预防及治疗提供依据。展开更多
目的探讨谷草转氨酶与血小板比值指数(aspartate aminotransferase-to-platelet ratio index,APRI)联合总胆汁酸(total bile acid,TBA)对胎龄<34周早产儿肠外营养相关性胆汁淤积症(parenteral nutritionassociated cholestasis,PNAC...目的探讨谷草转氨酶与血小板比值指数(aspartate aminotransferase-to-platelet ratio index,APRI)联合总胆汁酸(total bile acid,TBA)对胎龄<34周早产儿肠外营养相关性胆汁淤积症(parenteral nutritionassociated cholestasis,PNAC)的预测价值。方法回顾性分析2019年1月—2022年9月在皖南医学院第一附属医院住院期间接受肠外营养(parenteral nutrition,PN)的270例胎龄<34周早产儿的临床资料,包括PNAC 128例和非PNAC 142例。比较两组的临床资料,通过多因素logistic回归分析探讨PNAC发生的预测因素,并采用受试者操作特征曲线(receiver operating characteristic curve,ROC曲线)评价APRI、TBA单独及二者联合预测PNAC的价值。结果PNAC组在PN 1、2及3周后的TBA水平均高于非PNAC组(P<0.05);PN 2、3周后PNAC组APRI均高于非PNAC组(P<0.05)。多因素logistic回归分析显示,PN 2周后APRI和TBA升高是早产儿发生PNAC的预测因素(P<0.05)。ROC曲线分析显示,PN 2周后APRI联合TBA预测PNAC发生的灵敏度、特异度及曲线下面积(area under the curve,AUC)分别为0.703、0.803、0.806;APRI联合TBA预测PNAC发生的AUC高于APRI、TBA单独预测的AUC(P<0.05)。结论在PN 2周后,APRI联合TBA对胎龄<34周早产儿PNAC的预测价值较高。展开更多
目的基于二维超声弹性成像技术(2D-SWE)联合APRI建立无创模型对门静脉高压检测价值进行评价,为无创检测门静脉高压提供借鉴。方法选择2019年2月至2022年1月收治的门静脉高压患者63例,依据肝静脉压力梯度(HVPG)的出血风险程度分为低危组(...目的基于二维超声弹性成像技术(2D-SWE)联合APRI建立无创模型对门静脉高压检测价值进行评价,为无创检测门静脉高压提供借鉴。方法选择2019年2月至2022年1月收治的门静脉高压患者63例,依据肝静脉压力梯度(HVPG)的出血风险程度分为低危组(<12 mm Hg)20例和高危组(≥12 mm Hg)43例。测定天冬氨酸氨基转移酶(AST)、血小板(PLT)、测量肝静脉压力梯度(HVPG)。通过2D-SWE检测肝硬度,建立2D-SWE联合APRI无创模型,分析检测效能。结果2D-SWE、APRI单独对HVPG均有较好的诊断效能,其中2D-SWE曲线下面积为0.785[95%CI(0.671~0.899)],灵敏度0.558,特异度0.90,最佳截断值为18.80 kPa。APRI曲线下面积为0.786[95%CI(0.669~0.903)],灵敏度0.674,特异度0.80,最佳截断值为0.7712。2D-SWE联合APRI构建联合模型的曲线下面积为0.819[95%CI(0.711~0.927)],灵敏度0.628,特异度0.90,优于单独模型。结论2D-SWE、APRI及2D-SWE-APRI联合模型对于门静脉高压均有一定评估的价值,联合模型效能更优,可为无创检测门静脉高压提供借鉴。展开更多
文摘AIM To assess the diagnostic value of FIB-4, aspartate aminotransferase-to-platelet ratio index(APRI), and liver stiffness measurement(LSM) in patients with hepatitis B virus infection who have persistently normal alanine transaminase(PNALT).METHODS We enrolled 245 patients with chronic hepatitis B: 95 in PNALT group, 86 in intermittently elevated alanine transaminase(PIALT1) group [alanine transaminase(ALT) within 1-2 × upper limit of normal value(ULN)], and 64 in PIALT2 group(ALT > 2 × ULN). All the patients received a percutaneous liver biopsy guided by ultrasonography. LSM, biochemical tests, and complete blood cell counts were performed.RESULTS The pathological examination revealed moderate inflammatory necrosis ratios of 16.81%(16/95), 32.56%(28/86), and 45.31%(28/64), and moderate liverfibrosis of 24.2%(23/95), 33.72%(29/86), and 43.75%(28/64) in the PNALT, PIALT1, and PIALT2 groups, respectively. The degrees of inflammation and liver fibrosis were significantly higher in the PIALT groups than in the PNALT group(P < 0.05). No significant difference was found in the areas under the curve(AUCs) between APRI and FIB-4 in the PNALT group; however, significant differences were found between APRI and LSM, and between FIB-4 and LSM in the PNALT group(P < 0.05 for both). In the PIALT1 and PIALT2 groups, no significant difference(P > 0.05) was found in AUCs for all comparisons(P > 0.05 for all). In the overall patients, a significant difference in the AUCs was found only between LSM and APRI(P < 0.05).CONCLUSION APRI and FIB-4 are not the ideal noninvasive hepatic fibrosis markers for PNALT patients. LSM is superior to APRI and FIB-4 in PNALT patients because of the influence of liver inflammation and necrosis.
基金Shenzhen Municipal Science and Technology Innovation Fund,Nos.CXZZ20130322170220544 and JCYJ20140411112047885
文摘AIM: To investigate the combined diagnostic accuracy of acoustic radiation force impulse(ARFI), aspartate aminotransferase to platelet ratio index(APRI) and Forns index for a non-invasive assessment of liver fibrosis in patients with chronic hepatitis B(CHB). METHODS: In this prospective study, 206 patients had CHB with liver fibrosis stages F0-F4 classified by METAVIR and 40 were healthy volunteers were measured by ARFI, APRI and Forns index separately or combined as indicated. RESULTS: ARFI, APRI or Forns index demonstrated a significant correlation with the histological stage(all P < 0.001). According to the AUROC of ARFI and APRI for evaluating fibrotic stages more than F2, ARFI showed an enhanced diagnostic accuracy than APRI(P < 0.05). The combined measurement of ARFI and APRI exhibited better accuracy than ARFI alone when evaluating ≥ F2 fibrotic stage(Z = 2.77, P = 0.006). Combination of ARFI, APRI and Forns index did not obviously improve the diagnostic accuracy compared to the combination of ARFI and APRI(Z = 0.958, P = 0.338). CONCLUSION: ARFI + APRI showed enhanced diagnostic accuracy than ARFI or APRI alone for significant liver fibrosis and ARFI + APRI + Forns index shows the same effect with ARFI + APRI.
文摘AIM To investigate the usefulness of aspartate aminotransferase to platelet ratio index(APRI) in predicting hepatocellular carcinoma(HCC) risk in primary biliary cholangitis(PBC).METHODS We identified PBC patients between 2000 and 2015 by searching the electronic medical database of a tertiary center. The hazard ratio(HR) of HCC with different risk factors was determined by Cox proportional hazards model. RESULTS One hundred and forty-four PBC patients were recru-ited. Patients were diagnosed at a median age of 57.8 years [interquartile range(IQR): 48.7-71.5 years), and 41(28.5%) patients had cirrhosis at baseline. The median follow-up duration was 6.9 years(range: 1.0-26.3 years). Twelve patients developed HCC, with an incidence rate of 10.6 cases per 1000 patient-years. The overall 5-, 10-and 15-year cumulative incidences of HCC were 2.3% 95%CI: 0%-4.8%), 8.4%(95%CI: 1.8%-14.5%) and 21.6%(6.8%-34.1%), respectively. Older age(HR = 1.07), cirrhosis(HR = 4.38) and APRI at 1 year after treatment(APRI-r1) > 0.54(HR = 3.94) were independent factors for HCC development. APRI-r1, when combined with treatment response, further stratified HCC risk(log rank P < 0.05). The area under receiver operating curve of APRI-r1 in predicting HCC was 0.77(95%CI: 0.64-0.88).CONCLUSION APRI-r1 can be used to predict the development of HCC in PBC patients. Combination of APRI-r1 with treatment response can further stratify the HCC risk.
文摘目的探究天冬氨酸转氨酶和血小板比率指数(aspartate aminotransferase-to-platelet ratio index,APRI)与妊娠期肝内胆汁淤积症(intrahepatic cholestasis of pregnancy,ICP)的相关性。方法选取安徽医科大学附属巢湖医院产科于2021年9月至2023年3月收治的70例ICP孕妇作为病例组,选择同期70名健康孕妇作为对照组。采用回顾性研究方法,收集并分析两组孕妇分娩前1周的一般资料及实验室资料,并用t检验进行两组间的比较。运用Pearson相关系数法分析APRI与总胆汁酸(total bile acid,TBA)相关性;Logistic回归分析APRI与ICP的关系,采用受试者操作特征(receiver operating characteristic,ROC)曲线评估APRI在ICP中的应用价值。结果ICP组的APRI(1.1±1.2)高于对照组(0.2±0.1),差异有统计学意义(P<0.05)。重度ICP组的APRI(1.9±2.2)与轻度ICP组(0.9±0.7)比较,差异无统计学意义(P>0.05)。在ICP组中,APRI与TBA呈正相关(r=0.657,P<0.05)。Logistic回归分析结果表明,APRI不是ICP发生的独立影响因素(P>0.05)。APRI的曲线下面积(area under the curve,AUC)为0.870(P<0.05)。结论APRI与ICP的发生及其发展有一定的相关性,而对ICP的病情评估未显示出确定价值。
文摘BACKGROUND Both tenofovir alafenamide(TAF)and tenofovir disoproxil fumarate(TDF)are the first-line treatments for chronic hepatitis B(CHB).We have showed switching from TDF to TAF for 96 weeks resulted in further alanine aminotransferase(ALT)improvement,but data remain lacking on the long-term benefits of TDF switching to TAF on hepatic fibrosis.AIM To assess the benefits of TDF switching to TAF for 3 years on ALT,aspartate aminotransferase(AST),and hepatic fibrosis improvement in patients with CHB.METHODS A single center retrospective study on 53 patients with CHB who were initially treated with TDF,then switched to TAF to determine dynamic patterns of ALT,AST,AST to platelet ratio index(APRI),fibrosis-4(FIB-4)scores,and shear wave elastography(SWE)reading improvement at switching week 144,and the associated factors.RESULTS The mean age was 55(28-80);45.3%,males;15.1%,clinical cirrhosis;mean baseline ALT,24.8;AST,25.7 U/L;APRI,0.37;and FIB-4,1.66.After 144 weeks TDF switching to TAF,mean ALT and AST were reduced to 19.7 and 21,respectively.From baseline to switching week 144,the rates of ALT and AST<35(male)/25(female)and<30(male)/19(female)were persistently increased;hepatic fibrosis was also improved by APRI<0.5,from 79.2%to 96.2%;FIB-4<1.45,from 52.8%to 58.5%,respectively;mean APRI was reduced to 0.27;FIB-4,to 1.38;and mean SWE reading,from 7.05 to 6.30 kPa after a mean of 109 weeks switching.The renal function was stable and the frequency of patients with glomerular filtration rate>60 mL/min was increased from 86.5%at baseline to 88.2%at switching week 144.CONCLUSION Our data confirmed that switching from TDF to TAF for 3 years results in not only persistent ALT/AST improvement,but also hepatic fibrosis improvement by APRI,FIB-4 scores,as well as SWE reading,the important clinical benefits of long-term hepatitis B virus antiviral treatment with TAF.
文摘目的:探讨aMAP(age-male-ALBI-platelet,aMAP)、天门冬氨酸氨基转移酶/血小板比率指数(aspartate aminotransferase-to-platelet ratio index,APRI)、基于4因子的肝纤维化指数(fibrosis index based on the 4 factors,FIB-4)及肝硬度值(liver stiffness measurement,LSM)评估乙型肝炎(乙肝)肝硬化患者食管胃静脉曲张(esophageal gastric varices,EGV)程度的价值。方法:选取2018年4月到2022年5月期间在上海交通大学医学院附属瑞金医院确诊并接受治疗的乙肝肝硬化患者114例,对其进行肝功能、血常规、LSM、胃镜等检查,根据计算公式计算aMAP、APRI、FIB-4。根据胃镜结果将患者分为无EGV组(39例)、轻度EGV组(30例)、中度EGV组(23例)及重度EGV组(22例),比较4组间的aMAP、APRI、FIB-4。采用受试者操作特征曲线(receiver operator characteristic curve,ROC曲线)分析aMAP、APRI、FIB-4及LSM评估乙肝肝硬化患者EGV程度的价值。结果:EGV患者(包括轻度、中度及重度EGV组)的aMAP、APRI、FIB-4、LSM均显著高于无EGV的患者,差异有统计学意义(P<0.05)。轻度、中度及重度EGV组间的aMAP、APRI、FIB-4差异均有统计学意义(P<0.05);轻度EGV组与中度、重度EGV组间LSM差异有统计学意义(P<0.05)。aMAP评估EGV程度的ROC曲线下面积(the area under ROC curve,AUROC)为0.76,灵敏度为85.9%,特异度为65.7%;APRI、FIB-4和LSM评估EGV程度的AUROC分别为0.86、0.85、0.79,灵敏度分别为81.30%、82.80%、88.40%,特异度分别为82.90%、77.10%、66.80%。aMAP、APRI、FIB-4和LSM对肝硬化患者是否合并EGV有较好诊断价值(P<0.05)。aMAP、APRI、FIB-4对乙肝肝硬化患者的EGV程度有一定诊断价值(P<0.05),但特异度较低。结论:aMAP、APRI、FIB-4及LSM诊断乙肝肝硬化患者伴EGV的价值较高,而aMAP、APRI及FIB-4对其EGV程度有一定评估价值,可作为不适合做胃镜患者评估EGV的补充参考,为EGV的预防及治疗提供依据。
文摘目的基于二维超声弹性成像技术(2D-SWE)联合APRI建立无创模型对门静脉高压检测价值进行评价,为无创检测门静脉高压提供借鉴。方法选择2019年2月至2022年1月收治的门静脉高压患者63例,依据肝静脉压力梯度(HVPG)的出血风险程度分为低危组(<12 mm Hg)20例和高危组(≥12 mm Hg)43例。测定天冬氨酸氨基转移酶(AST)、血小板(PLT)、测量肝静脉压力梯度(HVPG)。通过2D-SWE检测肝硬度,建立2D-SWE联合APRI无创模型,分析检测效能。结果2D-SWE、APRI单独对HVPG均有较好的诊断效能,其中2D-SWE曲线下面积为0.785[95%CI(0.671~0.899)],灵敏度0.558,特异度0.90,最佳截断值为18.80 kPa。APRI曲线下面积为0.786[95%CI(0.669~0.903)],灵敏度0.674,特异度0.80,最佳截断值为0.7712。2D-SWE联合APRI构建联合模型的曲线下面积为0.819[95%CI(0.711~0.927)],灵敏度0.628,特异度0.90,优于单独模型。结论2D-SWE、APRI及2D-SWE-APRI联合模型对于门静脉高压均有一定评估的价值,联合模型效能更优,可为无创检测门静脉高压提供借鉴。
